- SpringWorks Therapeutics (NASDAQ:SWTX) has achieved full enrollment in its Phase 3 DeFi trial evaluating nirogacestat, an investigational gamma secretase inhibitor, in adult patients with progressing desmoid tumors.
- Top line results from the trial are expected in Q2 or Q3 2021.
- Desmoid tumors are rare and often debilitating and disfiguring soft tissue tumors characterized by a growth pattern that can invade surrounding healthy tissues, including joints, muscle and viscera.
- The study was designed to enroll 118 patients. The primary endpoint is progression-free survival, and secondary endpoints include safety and tolerability measures, as well as objective response rate, and changes in tumor volume assessed by MRI.
SpringWorks completes enrollment in late-stage nirogacestat study in connective tissue tumors
Recommended For You
More Trending News
About SWTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SWTX | - | - |
SpringWorks Therapeutics, Inc. |